Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.
Igarashi A, Tanaka S, De Moor R, Li N, Hirozane M, Wu DB, Hong LW, Yu DY, Hashim M, Hutton B, Tantakoun K, Olsen C, Fashami FM, Samjoo IA, Cameron C. Igarashi A, et al. Among authors: de moor r. Adv Ther. 2025 Jan 6. doi: 10.1007/s12325-024-03087-2. Online ahead of print. Adv Ther. 2025. PMID: 39760977 No abstract available.
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.
Igarashi A, Tanaka S, De Moor R, Li N, Hirozane M, Wu DB, Hong LW, Yu DY, Hashim M, Hutton B, Tantakoun K, Olsen C, Fashami FM, Samjoo IA, Cameron C. Igarashi A, et al. Among authors: de moor r. Adv Ther. 2024 Nov 12. doi: 10.1007/s12325-024-03013-6. Online ahead of print. Adv Ther. 2024. PMID: 39531127 Review.
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
Gutner CA, van der Valk M, Portilla J, Jeanmaire E, Belkhir L, Lutz T, DeMoor R, Trehan R, Scherzer J, Pascual-Bernáldez M, Ait-Khaled M, Hernandez B, de Ruiter A, Anand SB, Low EL, Hadi M, Barnes N, Sevdalis N, Mohammed P, Czarnogorski M. Gutner CA, et al. J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837. J Int Assoc Provid AIDS Care. 2024. PMID: 39221544 Free PMC article.
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
Jonsson-Oldenbüttel C, Ghosn J, van der Valk M, Florence E, Vera F, De Wit S, Rami A, Bonnet F, Hocqueloux L, Hove K, Ait-Khaled M, DeMoor R, Bontempo G, Latham CL, Gutner CA, Iyer S, Gill M, Czarnogorski M, D'Amico R, van Wyk J. Jonsson-Oldenbüttel C, et al. J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):472-480. doi: 10.1097/QAI.0000000000003448. Epub 2024 Jul 9. J Acquir Immune Defic Syndr. 2024. PMID: 38985445 Free PMC article. Clinical Trial.
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M. Gutner CA, et al. J Int AIDS Soc. 2024 Jul;27(7):e26243. doi: 10.1002/jia2.26243. J Int AIDS Soc. 2024. PMID: 38978405 Free PMC article. Clinical Trial.
A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices.
Tanaka S, Igarashi A, De Moor R, Li N, Hirozane M, Hong LW, Wu DB, Yu DY, Hashim M, Hutton B, Tantakoun K, Olsen C, Mirzayeh Fashami F, Samjoo IA, Cameron C. Tanaka S, et al. Among authors: de moor r. Value Health. 2024 Sep;27(9):1179-1190. doi: 10.1016/j.jval.2024.05.015. Epub 2024 Jun 4. Value Health. 2024. PMID: 38843980 Free article. Review.
Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial.
Mazur NI, Löwensteyn YN, Terstappen J, Leusen J, Schobben F, Cianci D, van de Ven PM, Nierkens S, Bont LJ; Narsyn Study Group. Mazur NI, et al. EClinicalMedicine. 2023 Nov 25;66:102324. doi: 10.1016/j.eclinm.2023.102324. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192587 Free PMC article.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Han K, Gevorkyan H, Sadik Shaik J, Crauwels H, Leemereise C, Bontempo G, Win B, Chounta V, Seal C, DeMoor R, D'Amico R, Spreen WR, Ford SL. Han K, et al. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0078123. doi: 10.1128/aac.00781-23. Epub 2023 Dec 1. Antimicrob Agents Chemother. 2024. PMID: 38038460 Free PMC article.
175 results